RESVERLOGIX CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.06 CAD | +9.09% |
|
+9.09% | -14.29% |
| Apr. 01 | Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 21 | Resverlogix Corp. Announces Resignation of Shawn Lu from the Board of Directors | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 14.37M 19.83M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -4.14M | Net income 2023 | -16M -22.07M | EV / Sales 2022 | - |
| Net Debt 2022 | 50.15M 69.19M | Net Debt 2023 | 70.94M 97.88M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-7.6
x | P/E ratio 2023 |
-0.85
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 44.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on Resverlogix Corp.
More press releases
More news
| 1 day | +9.09% | ||
| 1 week | +9.09% | ||
| Current month | +9.09% | ||
| 3 months | -14.29% | ||
| 6 months | -7.69% | ||
| Current year | -14.29% |
1 week
0.06
0.06
1 month
0.060.06
Current year
0.060.07
1 year
0.060.17
3 years
0.060.96
5 years
0.064.94
10 years
0.064.94
| Managers | Title | Age | Since |
|---|---|---|---|
Donald McCaffrey
CEO | Chief Executive Officer | - | 00-08-16 |
Anthony Cann
DFI | Director of Finance/CFO | 76 | 09-10-25 |
| Chief Tech/Sci/R&D Officer | - | 04-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kenneth Zuerblis
BRD | Director/Board Member | 64 | 10-09-28 |
Donald McCaffrey
CEO | Chief Executive Officer | - | 00-08-16 |
Kelly McNeill
BRD | Director/Board Member | 54 | 09-10-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 0.06 | +9.09% | 7,500 |
| 24-04-12 | 0.055 | 0.00% | 10,900 |
| 24-04-11 | 0.055 | 0.00% | 10,000 |
| 24-04-10 | 0.055 | 0.00% | 69,000 |
Delayed Quote Toronto S.E., April 15, 2024 at 09:59 am EDT
More quotes
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -14.29% | 11.97M | |
| -2.34% | 103B | |
| +2.31% | 96.56B | |
| +1.02% | 22.61B | |
| -16.72% | 21.18B | |
| -3.29% | 19.07B | |
| -41.75% | 16.53B | |
| -23.26% | 14.46B | |
| -0.02% | 13.25B | |
| +22.69% | 11.1B |
- Stock Market
- Equities
- RVX Stock
